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Background/aim: Alpha- and beta-amanitins are the main toxins of the poisonous Amanita phalloides mushroom. Although there are
many studies available concerning alpha-amanitin, there are limited data about beta-amanitin in the literature. Therefore, this study is
aimed at comparing the toxic effects of alpha- and beta-amanitin on the MCF-7 cell line.
Materials and methods: The alpha- and beta-amanitins used for this research were purified from Amanita phalloides by preparative
high-performance liquid chromatography. The MCF-7 breast cancer cell line was used, and specific concentrations of the toxins (100,
10, 1, 0.1, and 0.01 µg/mL) were applied to the cells. The MTT test was performed to determine the level of toxicity, and the quantity of
protein in the cell was measured using the biuret test.
Results: The alpha-amanitin showed a higher toxicity at 36 h, while the highest inhibition of protein synthesis by the beta-amanitin was
observed at 24 h.
Conclusion: It was shown that the beta-amanitin may be responsible for toxicity, like alpha-amanitin, in Amanita phalloides mushroom
poisoning. The early inhibition of protein synthesis for beta-amanitin might be useful for future experiments and research.
Key words: Alpha-amanitin, beta-amanitin, MCF-7 cell line, mycotoxins

1. Introduction
Deaths from mushroom poisoning, due to the ingestion of
mushrooms containing amatoxins, seem to be increasing
both in Turkey and worldwide (1). The alpha-amanitin
(α-AMA) found in Amanita phalloides (also called the
death cap mushroom) is one of the most toxic agents, and
it is responsible for more than 90% of the cases of deadly
mushroom poisoning (2). The oral 50% lethal dose (LD50)
of α-AMA is 0.1 mg/kg for mice, and a single mushroom
can contain a fatal dose (10–12 mg) large enough for
a human (3). In addition to α-AMA, several amatoxins,
including beta amanitin (β-AMA), gamma-amanitin,
amanullin, and amanullinic acid, have been identified in
this mushroom (4).
Amatoxins are also known as cyclopeptides because
they consist of 8 amino acids in a circular chain. The sulfur
atom in the cysteine amino acid converts the structure from
the cyclic to bicyclic form by bonding with the indolamine
group in the amino acid tryptophan. The tryptathionine
* Correspondence: kursatyay@yahoo.com
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moiety and bicyclic structure of the amatoxins are
mainly responsible for toxicity, and the toxin diversity
in the mushroom emerges from the chemical changes in
the main structure (5,6). The quantities of α-AMA and
β-AMA are similar, and these toxins have been found more
commonly than any other toxins in the mushrooms (7,8).
The α-AMA and β-AMA have similar structures, except in
the R substituent. α-AMA contains an amino group and is
neutral, while β-AMA contains carboxyl and is acidic (9).
Amatoxins are heat-stable octapeptides, and it has been
demonstrated that the stability of α-AMA in water and
methanol is maintained at different temperatures, even
after 6 months (10,11).
The uptake of amanitin into hepatocytes is mediated by
a transport system (12,13). While it does not show a direct
cytolytic effect, it inhibits eukaryotic RNA polymerase II.
In this way, α-AMA causes cell death by inhibiting the
transcription of DNA and protein synthesis (14–16). The
damage to the liver and kidneys caused by α-AMA depends
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on the received dose. The mortality rate after digestion is
very high, and irreversible liver failure may result in death
within 3 to 7 days (17).
In vitro and in vivo investigations have demonstrated
that α-AMA may cause apoptotic cell death as well as
hepatocyte necrosis. Experiments performed on canine
hepatocyte cultures have shown that apoptosis plays a
vital role in the pathogenesis of hepatic damage caused
by α-AMA intoxication (2,18). The α-AMA–induced
apoptosis is associated with severe liver damage, especially
in the early stages of poisoning (18); however, a nonlethal
dose of α-AMA prevents DD1 (a novel death domain)mediated apoptosis by disrupting the protein synthesis.
In fact, this process is under investigation in cell culture
experiments either alone or in combination with other
medicines for the treatment of cancer (19–21). The
cytotoxic effect of β-AMA has been shown in a few studies,
but the stability of β-AMA has not been investigated in
detail (22–24).
There are several papers related to the toxicity of
α-AMA, but there are no studies investigating both α-AMA
and β-AMA toxicity. In the present study, the evaluation
and the comparison of α-AMA and β-AMA toxicity on the
MCF-7 cell line were conducted.
2. Materials and methods
From Amanita phalloides, α-AMA and β-AMA were
isolated with >99% purity using a preparative highperformance liquid chromatography (HPLC) method
and were quantified using an analytical HPLC method,
as described previously. The mushrooms were classified
systematically based on their microscopic and macroscopic
characteristics, were dried under flowing air at 50 °C for 12
h, and were crushed. The extracts were prepared in 50%
methanol, and they were applied to the preparative HPLC
system twice. The fractions of α-AMA and β-AMA were
collected according to their retention time, and the purity
of the toxins was confirmed using the analytical HPLC
system. The obtained toxin’s purity was higher than 99%
(25,26).
The human breast cancer cell line, MCF-7, was
obtained from the American Type Culture Collection.
Dulbecco’s Modified Eagle Medium (Invitrogen, USA) and
fetal bovine serum (Invitrogen) were used as the medium
and serum, respectively. The MCF-7 cells were incubated
in 5% CO2 at 37 °C, and the toxins were applied to the cell
culture medium at 100, 10, 1, 0.1, and 0.01 µg/mL final
concentrations after being dissolved in water and were
incubated for specific time periods.
2.1. Determination of cell viability
The MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide] was used to evaluate the
overall functional integrity and viability of the cultured

cells (17). The MCF-7 cells were put into 96-well plates (2
× 104 for each well), which were incubated for 24 h. The
specific concentrations of α-AMA and β-AMA were added
to the cell culture medium, and plates were incubated for
an additional 36 h. MTT solution (1:10 ratio) and dimethyl
sulfoxide (DMSO) (100 µL) were then added to the cell
culture medium and plates were incubated overnight. The
absorbance was measured at 570 nm on a plate reader. This
experiment was repeated 3 times. The absorbance data
were calculated as percentages according to the control
group.
2.2. Measurement of the total protein
The total protein was measured using the biuret test
(27). After harvesting the MCF-7 cells, the lysis buffer
(Caspase-3 Colorimetric Kit, Invitrogen) was added to the
cell pellet, which was chilled on ice for 10 min. The samples
and separate concentrations (0, 1, 2, 4, 8, 16, and 32 mg/
mL) of bovine serum albumin were added to 96-well
plates, and 90 µL of biuret solution was added to each well.
The samples were then incubated at room temperature
for 15 min. The absorbance was measured at 570 nm on
an ELISA reader, and the total protein concentrations for
the samples were calculated according to the calibration
graph. This experiment was repeated 3 times.
2.3. Statistical analysis
Statistical analyses were performed using PASW 18
statistical software (ver. 18.0 for Windows; SPSS Inc.,
USA), and the data were analyzed using 2-factor ANOVA
and Tukey’s tests. The level of statistical significance was
set at P < 0.05.
3. Results
3.1. α-AMA showed more toxicity than β-AMA
According to the MTT test data, α-AMA decreased cell
viability by 14%, 21%, 41%, 44%, and 50% at concentrations
of 100, 10, 1, 0.1, and 0.01 µg/mL, respectively. The LD50
of the α-AMA at 36 h was measured as 1 µg/mL, and
statistical significance was obtained in terms of cell death
at this dose and higher doses (P < 0.05). Similarly, the rates
of cell viability were calculated as 52%, 62%, 84%, 86%, and
91% at concentrations of 100, 10, 1, 0.1, and 0.01 µg/mL,
respectively, for the β-AMA. The LD50 of the β-AMA at 36
h was measured as 10 µg/mL, and statistical significance
was obtained in terms of cell death at this dose and higher
doses (P < 0.05) (Figure 1). The α-AMA showed greater
toxicity than the β-AMA at 36 h.
3.2. β-AMA inhibits the protein synthesis earlier than
α-AMA
The β-AMA showed a greater inhibition of protein
synthesis at both concentrations (10 µg/mL and 1 µg/mL)
for 24 h (P < 0.05). The total amount of protein within
the cell at 24 h was significantly increased for the 1 µg/
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Figure 1. The rate of cell viability after toxin treatment. The
cell line was stimulated by α- and β-amanitin at certain
concentrations. After incubation for 36 h, the MTT test was
performed to evaluate the cell viability (*: statistical difference
between toxin and control groups, #: statistical difference
between α- and β-amanitin groups).

mL dose of α-AMA compared to the control (P < 0.05).
In contrast, the total amount of protein within the cell at
24 h was significantly decreased for the 10 µg/mL dose of
β-AMA when compared to the control (P < 0.05) (Figure
2).
4. Discussion
Cases of mushroom poisoning are most often the result
of Amanita phalloides ingestion, with its main toxins
being amatoxins. It is assumed that α-AMA is the most
toxic agent in the mushroom, but the toxicity of β-AMA
is not known in detail. Clarification of this issue may help
to develop new emergency treatment methods in cases
of mushroom poisoning. In this study, the toxicity of αand β-AMA were evaluated and compared in the MCF-7
breast cancer cell line.
α-AMA has a hepatotoxic effect, and its uptake into
hepatocytes is mediated by a special transport system
(12,13). However, it was reported that α-AMA penetrates
into tumor cells by receptor-mediated endocytosis (29).
To evaluate the purely toxic effects of amatoxins, cell lines
other than hepatocytes were used in this investigation.
For our purposes, several cell lines, such as MCF-7 (breast
cancer) (20), BxPC-3 and CAPAN-1 (human pancreatic
carcinoma), Colo205 (colorectal carcinoma), OZ (bile duct
carcinoma) (21), A431 (epidermoid carcinoma) (22), and
L1210 (lymphocytic leukemia) (23) cells, were considered.
Five different concentrations of toxins were applied to
MCF-7 cell lines, and the toxicities were evaluated after 36
h. The data obtained show that the LD50 was 1 µg/mL for
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Figure 2. The level of total protein within the cell after toxin
treatment. The cell line was stimulated by α- and β-amanitin
at certain concentrations. After incubation for 36 h, the biuret
test was performed to determine the protein levels (*: statistical
difference between toxin and control groups, #: statistical
difference between α- and β-amanitin groups).

α-AMA and 10 µg/mL for β-AMA. Therefore, the toxicity
of α-AMA is greater than that of β-AMA. Similar results
were obtained in several studies; for example, Magdalan
et al. evaluated the toxicity of α-AMA in hepatocytes at
certain concentrations, and comparable results were
obtained from their findings (2). The cytotoxicity of
β-AMA has been investigated in a limited number of
studies and was demonstrated in A431 (22) and L1210
lymphocytic leukemia cell lines (23,24). It can be concluded
from the literature data that the cytotoxicity increases as
the concentration of α-AMA increases (13).
The putative mechanisms of α-AMA causing toxicity
are currently under debate. α-AMA does not show a direct
cytolytic effect, but it does block DNA transcription by
inhibiting the RPB1 subunit of RNA polymerase II, leading
to cell death (15,16). Additionally, α-AMA induces both
necrotic and apoptotic cell death concomitantly in the
hepatocytes, where elevated cellular apoptosis is especially
emphasized (2,18). In human fibroblasts and human colon
carcinoma cell line 116 (HTC116), α-AMA was shown
to induce the accumulation of p53 in the mitochondria,
which leads to p53- and caspase-dependent apoptosis
(16,21,30–32). The inhibition of apoptosis by α-AMA was
also suggested (19,20).
The other mechanism for α-AMA toxicity is its
involvement in free radical reactions. An increase in
superoxide dismutase activity and decrease in catalase
activity after treatment with α-AMA was determined by
Zheleva et al. Therefore, α-AMA has a prooxidative or
antioxidant effect, depending on the toxin concentrations
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(33). The roles of oxidative stress in hepatotoxicity and
hepatocyte apoptosis have been reported before, and it
can be concluded that an increase in the reactive oxygen
species level induced by α-AMA probably increases liver
toxicity, contributing to hepatocyte membrane damage
(34,35). In addition, α-AMA was found to decrease the
expression of transcription factor nuclear factor erythroid
2 (NF-E2) related factor 2 (NRF2).
It is well characterized that NRF2 stimulates the
antioxidant defense system in response to oxidative stress,
and it could be speculated that the decreased expression
of NRF2 by α-AMA may be involved in the cytotoxicity
of α-AMA (36). Furthermore, tumor necrosis factoralpha aggravates the α-AMA cytotoxicity by a mechanism
that may involve reactive oxygen species (37,38). There are
several putative mechanisms of α-AMA causing toxicity,
but these have not been clarified in detail.
β-AMA inhibited the total protein synthesis more than
α-AMA at the end of 24 h after the treatment of the MCF7 cells with the toxins. There may be several reasons for
this, but the most plausible reason is that β-AMA might
penetrate into the cells more easily and quickly and begin
to inhibit protein synthesis earlier than α-AMA. These
amatoxins have a similar structure, and they mainly consist
of 8 amino acid residues, arranged in bicyclic octapeptides
to form a pentacyclic structure, having 5 different
changeable positions. The structural difference between
α-AMA and β-AMA is an amino group (NH2) at the third
position. The NH2 group is present in α-AMA, while the
hydroxyl (OH) group is present in β-AMA (39,40). This
difference causes the altered pharmacokinetics of the
toxins (41).
In addition, a study done by Tinnikov et al. revealed
that the penetration of α-AMA into cells is relatively
slow and depends on the concentration and cell type

(20). Receptor-mediated endocytosis may be partially
responsible for this slow rate (29). These data are consistent
with our experimental data. In our experiment, the cells
were treated with toxins for 24 h; however, treatment for
longer than 24 h might be needed to clarify the inhibition
of protein synthesis in detail. This is a limitation of our
study.
The total protein quantity within the cell was
decreased in the treatment with 10 µg/mL β-AMA, but
it was increased in the treatment with 1 µg/mL α-AMA
for 24 h when compared to the control. This result was
not consistent with earlier hepatocyte culture studies (2),
and the putative reason may be the cell type. It was also
reported that α-AMA has antiapoptotic characteristics,
which could also be the reason (19,20).
In addition to toxicity, recent studies have showed
that amanitins exhibit retardation activity on tumor cells
and ectoparasites without affecting somatic cell activity.
Therefore, α-AMA has the potential for use as a medicine
for the therapy of diseases like cancer or ectoparasitic
infections (20,21,42,43).
In conclusion, our study is the first to evaluate and
compare the cytotoxicity of α-AMA and β-AMA in the
same conditions. We concluded that both toxins have
cytotoxic effects, but those of α-AMA are a little higher.
β-AMA also has toxic effects in mushroom poisoning,
and alternative therapies targeting β-AMA should be
developed in hepatotoxicity investigations. In addition,
both toxins have potential uses in new therapy methods
for cancer but require further investigation.
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